{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:35Z","timestamp":1789632215447,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dld.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:35:15Z","timestamp":1780461315000},"page":"1051-1060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-7541","authenticated-orcid":false,"given":"Franco","family":"Scaldaferri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-7641","authenticated-orcid":false,"given":"Federica","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro Marco","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Giuseppe","family":"Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Aloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Alivernini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Scolieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-6262","authenticated-orcid":false,"given":"Paola","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneida","family":"Cela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Laura","family":"Bosello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-0421","authenticated-orcid":false,"given":"Emma","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-9232","authenticated-orcid":false,"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cammarota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Capacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cicala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Americo","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Corsano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Picchianti-Diamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7964-3348","authenticated-orcid":false,"given":"Eugenio","family":"Di Brino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Faggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-3050","authenticated-orcid":false,"given":"Stefano","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Laterza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Lopetuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Mensurati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7333-371X","authenticated-orcid":false,"given":"Gerlando","family":"Natalello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-0939","authenticated-orcid":false,"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severino","family":"Persechino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1097-9430","authenticated-orcid":false,"given":"Roberta","family":"Pica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1055-160X","authenticated-orcid":false,"given":"Pietro","family":"Refolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Richetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-3018","authenticated-orcid":false,"given":"Dario","family":"Sacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-2164","authenticated-orcid":false,"given":"Antonio Gioacchino","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Zampaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Petrangolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.dld.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/ijd.16677","article-title":"Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis","volume":"62","author":"McCoy","year":"2023","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.dld.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","article-title":"The cost of inflammatory bowel disease care: how to make it sustainable","volume":"23","author":"Burisch","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/mr\/roac038","article-title":"Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: three approaches with a cohort simulation and real-world data","volume":"33","author":"Kuwana","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.dld.2026.05.004_bib0004","article-title":"Association between systemic inflammation indicators and psoriasis: a cross-sectional study from NHANES","volume":"16","author":"Xiong","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MEG.0000000000002842","article-title":"The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients","volume":"37","author":"Cesaro","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.dld.2026.05.004_bib0006","first-page":"00900","article-title":"Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis","volume":"S0003-4967","author":"Steinz","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0008","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s13555-025-01423-0","article-title":"Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"15","author":"Lebwohl","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/00365521.2025.2491013","article-title":"Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"60","author":"Tianeze de Castro","year":"2025","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-025-02192-y","article-title":"Navigating psoriatic arthritis: treatment pathways and patient-specific strategies for improved outcomes","volume":"85","author":"Queiro","year":"2025","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.dld.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.3390\/jcm13175139","article-title":"IL-17 and IL-23 inhibitors have the fastest time to meaningful clinical response for plaque psoriasis: a network meta-analysis","volume":"13","author":"Aggarwal","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s13555-024-01105-3","article-title":"Correction to: comparative effectiveness and durability of biologics in clinical practice: month 12 outcomes from the international, observational psoriasis study of health outcomes (PSoHO)","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/00365521.2014.993700","article-title":"New targeted therapies such as anti-adhesion molecules, anti-IL-12\/23 and anti-janus kinases are looking toward a more effective treatment of inflammatory bowel disease","volume":"50","author":"Bravat\u00e0","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/jgh.16936","article-title":"Real-world effectiveness and safety of Vedolizumab in patients \u2265\u200970 versus <\u200970\u2009years with ulcerative colitis: multicenter retrospective study","volume":"40","author":"Hisamatsu","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40744-024-00684-z","article-title":"Matching-adjusted indirect comparison of the 52-week efficacy of Bimekizumab versus Secukinumab and Ixekizumab for the treatment of radiographic axial spondyloarthritis","volume":"11","author":"Maksymowych","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"11","key":"10.1016\/j.dld.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/ijd.16849","article-title":"Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas","volume":"62","author":"Vaiopoulos","year":"2023","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s10067-025-07390-3","article-title":"Comparative analysis of clinical profile, therapeutic management, and clinical prognosis of patients with seropositive or seronegative rheumatoid arthritis following the introduction of a first targeted therapy in a real-life setting","volume":"44","author":"Angelozzi","year":"2025","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.dld.2026.05.004_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1488357","article-title":"JAK inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiology","volume":"16","author":"Ciccia","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/RHU.0000000000002232","article-title":"Comparative efficacy and safety of different regimens of current JAK inhibitors in psoriatic arthritis: a network meta-analysis","volume":"31","author":"Wan","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.dld.2026.05.004_bib0022","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v105.42990","article-title":"Real-world effectiveness and safety of Janus Kinase inhibitors in Alopecia Areata: a retrospective cohort study of 72 patients","volume":"105","author":"Van Helmond","year":"2025","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13555-025-01397-z","article-title":"Efficacy and safety of JAK inhibitors in the management of vitiligo: a systematic review and meta-analysis","volume":"15","author":"Mohammed","year":"2025","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0024","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1186\/s12913-021-06866-7","article-title":"A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study","volume":"21","author":"Zagni","year":"2021","journal-title":"BMC Health V Res"},{"key":"10.1016\/j.dld.2026.05.004_bib0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/CEOR.S417922","article-title":"The cost-effectiveness of anti-IL17 biologic therapies for moderate-to-severe plaque psoriasis treatment in Italy and Germany: a sequential treatment analysis","volume":"Volume 15","author":"Nyholm","year":"2023","journal-title":"Clin Outcomes Res"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0026","first-page":"663","article-title":"Biosimilars for the treatment of psoriasis: a narrative review","volume":"159","author":"Phan","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"issue":"2","key":"10.1016\/j.dld.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ueg2.12717","article-title":"The impact of Ustekinumab Biosimilar on therapeutic strategies in Crohn\u2019s Disease: a paradigm shift?","volume":"13","author":"Bezzio","year":"2025","journal-title":"United Eur Gastroenterol J"},{"issue":"2","key":"10.1016\/j.dld.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/0929867324666170406112304","article-title":"Biosimilars for the management of inflammatory bowel diseases: economic considerations","volume":"26","author":"Gulacsi","year":"2019","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ad.2015.04.008","article-title":"Biosimilars in dermatology: current situation (part II)","volume":"106","author":"Puig","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.dld.2026.05.004_bib0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fphar.2018.00794","article-title":"Quality of life and cost study of rheumatoid arthritis therapy with biological medicines","volume":"9","author":"Boyadzieva","year":"2018","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.dld.2026.05.004_bib0031","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.dld.2022.07.004","article-title":"Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study","volume":"54","author":"Lontai","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2023-001105","article-title":"Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)","volume":"10","author":"Carbery","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0033","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ecco-jcc\/jjz192","article-title":"The sooner the better? Cost-effectiveness of early biological therapy in patients with Crohn\u2019s Disease","volume":"14","author":"Zhao","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.dld.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5694\/mja15.00716","article-title":"Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia","volume":"204","author":"Hopkins","year":"2016","journal-title":"Med J Aust"},{"issue":"10","key":"10.1016\/j.dld.2026.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40273-016-0409-9","article-title":"A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy","volume":"34","author":"Tappenden","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1002\/hec.1035","article-title":"The Italian health-care system","volume":"14","author":"France","year":"2005","journal-title":"Health Econ"},{"issue":"14","key":"10.1016\/j.dld.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1080\/00036840210126809","article-title":"The regional impact of health care expenditure: the case of Italy","volume":"34","author":"Giannoni","year":"2002","journal-title":"Appl Econ"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0038","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/eurpub\/ckq029","article-title":"Equity in access to health care in Italy: a disease-based approach","volume":"20","author":"Masseria","year":"2010","journal-title":"Eur J Public Health"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(20)30074-8","article-title":"The Italian health system and the COVID-19 challenge","volume":"5","author":"Armocida","year":"2020","journal-title":"Lancet Public Health"},{"issue":"3","key":"10.1016\/j.dld.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1517\/14712598.2013.735654","article-title":"Economical aspect of biological therapy in inflammatory conditions in Hungary","volume":"13","author":"Laki","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0041","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10067-025-07368-1","article-title":"Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis","volume":"44","author":"Xie","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0042","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/13696998.2023.2299176","article-title":"Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia","volume":"27","author":"Al-Abdulkarim","year":"2024","journal-title":"J Med Econ"},{"issue":"2\u20133","key":"10.1016\/j.dld.2026.05.004_bib0043","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.healthpol.2011.10.003","article-title":"Quasi-market and cost-containment in Beveridge systems: the Lombardy model of Italy","volume":"103","author":"Brenna","year":"2011","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0044","doi-asserted-by":"crossref","first-page":"68","DOI":"10.33393\/grhta.2024.2677","article-title":"Regional formularies in Italy: current state and future perspectives","volume":"11","author":"Bortolami","year":"2024","journal-title":"Grhta"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2026.05.004_bib0045","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.33393\/grhta.2016.306","article-title":"Il governo dell\u2019innovazione farmaceutica in Italia: quali strumenti di governance regionale proporre?: managing pharmaceutical innovation in Italy: which regional governance tools can be adopted?","volume":"3","author":"Nuti","year":"2016","journal-title":"Grhta"},{"key":"10.1016\/j.dld.2026.05.004_bib0046","series-title":"OECD reviews of health systems: romania 2025 [Internet]","author":"OECD","year":"2025"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0047","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.canep.2012.06.006","article-title":"Regional inequalities in cancer care persist in Italy and can influence survival","volume":"36","author":"Sant","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.dld.2026.05.004_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/OP-24-00804","article-title":"Environmental impact assessment of intravenous versus subcutaneous monoclonal antibodies: a carbon footprint analysis","author":"Zietse","year":"2025","journal-title":"JCO Oncol Pr"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0049","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"issue":"3","key":"10.1016\/j.dld.2026.05.004_bib0050","first-page":"317","article-title":"Book review: the Delphi method: techniques and applications","volume":"13","author":"Mahajan","year":"1976","journal-title":"J Mark Res"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0051","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12874-020-0912-8","article-title":"Comparison of different rating scales for the use in Delphi studies: different scales lead to different consensus and show different test-retest reliability","volume":"20","author":"Lange","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.dld.2026.05.004_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.futures.2020.102605","article-title":"A multi-stakeholder perspective on sustainable healthcare: from 2030 onwards","volume":"122","author":"Pereno","year":"2020","journal-title":"Futures"},{"issue":"3","key":"10.1016\/j.dld.2026.05.004_bib0054","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"International Joint Task Group. The new definition of health technology assessment: a milestone in international collaboration","volume":"36","author":"O\u2019Rourke","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"issue":"10","key":"10.1016\/j.dld.2026.05.004_bib0056","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s40520-021-01922-y","article-title":"The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID-19 pandemic","volume":"33","author":"Monaco","year":"2021","journal-title":"Aging Clin Exp Res"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0057","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/antibiotics11040468","article-title":"Impact of guideline adherence on outcomes in patients hospitalized with community-acquired pneumonia (CAP) in Hungary: a retrospective observational study","volume":"11","author":"F\u00e9s\u00fcs","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.dld.2026.05.004_bib0058","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/PPA.S165101","article-title":"Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review","volume":"12","author":"Anghel","year":"2018","journal-title":"PPA"},{"issue":"2","key":"10.1016\/j.dld.2026.05.004_bib0059","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5334\/ijic.7741","article-title":"New model of integrated care for patients with immune-mediated inflammatory diseases","volume":"25","author":"Chamorro-de-Vega","year":"2025","journal-title":"Int J Integr Care"},{"key":"10.1016\/j.dld.2026.05.004_bib0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vhri.2020.04.003","article-title":"Limitations and challenges of conducting budget impact analyses in rare diseases: a case study of alpha-1 antitrypsin deficiency","volume":"23","author":"Rueda","year":"2020","journal-title":"Value Health Reg Issues"},{"issue":"10","key":"10.1016\/j.dld.2026.05.004_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70230","article-title":"Trajectories of adherence to biologics in patients with inflammatory bowel diseases: a large-scale multi-regional Italian study through the VALORE distributed database","volume":"34","author":"Giometto","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.dld.2026.05.004_bib0062","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33393\/dti.2021.2342","article-title":"The role of patient preferences in adherence to treatment in chronic disease: a narrative review","volume":"15","author":"Losi","year":"2021","journal-title":"dti"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0063","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12325-016-0441-3","article-title":"Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study","volume":"34","author":"Michetti","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.dld.2026.05.004_bib0064","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1046\/j.1524-4733.6.s1.1.x","article-title":"The drug budget silo mentality in Europe: an overview","volume":"6","author":"Garrison","year":"2003","journal-title":"Value Health"},{"issue":"24","key":"10.1016\/j.dld.2026.05.004_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph182413413","article-title":"The challenge of sustainability of high-cost oncological drugs: a budgeting model in an Italian cancer center","volume":"18","author":"Masini","year":"2021","journal-title":"Int J Env Res Public Health"},{"key":"10.1016\/j.dld.2026.05.004_bib0066","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jclinepi.2016.12.022","article-title":"Series: pragmatic trials and real world evidence: paper 6. Outcome measures in the real world","volume":"90","author":"Welsing","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.dld.2026.05.004_bib0067","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jclinepi.2017.05.004","article-title":"Series: pragmatic trials and real world evidence: paper 7. Safety, quality and monitoring","volume":"91","author":"Irving","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0068","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharm Med"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0069","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-020-00221-y","article-title":"Real-world evidence: bridging gaps in evidence to guide payer decisions","volume":"5","author":"Roberts","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0070","first-page":"30","article-title":"[Psychosomatic aspects of dental prosthetic treatment (II)]","volume":"94","author":"Forberger","year":"1985","journal-title":"ZWR"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0071","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0072","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0073","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.05.004_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102915","article-title":"Real-world data: bridging the gap between clinical trials and practice","volume":"78","author":"Wilson","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.dld.2026.05.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145087","article-title":"A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases","volume":"10","author":"Huoponen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2026.05.004_bib0076","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CEOR.S39212","article-title":"A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases","volume":"6","author":"Odes","year":"2014","journal-title":"Clin Outcomes Res"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0077","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ecco-jcc\/jjz169","article-title":"Evaluating the cost-effectiveness of early compared with late or No biologic treatment to manage Crohn\u2019s disease using real-world data","volume":"14","author":"Pillai","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2026.05.004_bib0078","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2147\/JMDH.S432820","article-title":"On the interdisciplinary treatment and management of patients with immune-mediated inflammatory diseases. A study on patients\u2019 Personal experiences and perspectives","volume":"Volume 17","author":"Hjuler","year":"2024","journal-title":"J Multidiscip Heal"},{"key":"10.1016\/j.dld.2026.05.004_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1290018","article-title":"A multidisciplinary dermatology-gastroenterology-rheumatology (DER.RE.GA) unit for the care of patients with immune-mediated inflammatory diseases: analysis of the first 5\u2009years from the dermatologist\u2019s perspective","volume":"10","author":"Brazzelli","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/17474124.1.1.101","article-title":"Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies","volume":"1","author":"Thomas","year":"2007","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.dld.2026.05.004_bib0081","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-016-1208-6","article-title":"36th International Symposium on Intensive Care and Emergency Medicine : brussels, Belgium. 15-18 March 2016","volume":"20","author":"Bateman","year":"2016","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0082","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/11584820-000000000-00000","article-title":"Cost effectiveness of treatments for inflammatory bowel disease","volume":"29","author":"Bodger","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.dld.2026.05.004_bib0083","article-title":"Overcoming silos in health care systems through meso-level organisations - a case study of health reforms in New South Wales, Australia","volume":"44","author":"Peiris","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"16","key":"10.1016\/j.dld.2026.05.004_bib0084","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2217\/fon-2021-1584","article-title":"Real-world evidence of a successful biosimilar adoption program","volume":"18","author":"Humphreys","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10961-024-10083-9","article-title":"Collaborative research in healthcare: uncovering the impact of industry collaboration on the service innovativeness of university hospitals","volume":"50","author":"Huynh","year":"2025","journal-title":"J Technol Transf"},{"key":"10.1016\/j.dld.2026.05.004_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2023.116332","article-title":"The role of patient organisations in research and development: evidence from rare diseases","volume":"338","author":"Gentilini","year":"2023","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.dld.2026.05.004_bib0087","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/AMEP.S175683","article-title":"Evolving role of pharmaceutical physicians in medical evidence and education","volume":"Volume 9","author":"Setia","year":"2018","journal-title":"Adv Med Educ Pr"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0088","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1017\/S0266462324004720","article-title":"The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms","volume":"41","author":"Vidalis","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"issue":"12","key":"10.1016\/j.dld.2026.05.004_bib0089","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s40273-025-01534-8","article-title":"The economic burden of inflammatory arthritis: a systematic review","volume":"43","author":"Zhang","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.dld.2026.05.004_bib0090","article-title":"The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study","volume":"4","author":"Galloway","year":"2020","journal-title":"Rheumatol Adv Pr"},{"issue":"3","key":"10.1016\/j.dld.2026.05.004_bib0091","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70117","volume":"34","author":"Hennessy","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0092","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s11096-025-01956-6","article-title":"Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence","volume":"47","author":"Yiu","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.dld.2026.05.004_bib0093","article-title":"Savings from biosimilars use in the Italian national health service","volume":"49","author":"Marino","year":"2025","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0094","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s11096-025-01956-6","article-title":"Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence","volume":"47","author":"Yiu","year":"2025","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.dld.2026.05.004_bib0096","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2217\/fon-2021-1584","article-title":"Real-world evidence of a successful biosimilar adoption program","volume":"18","author":"Humphreys","year":"2022","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.dld.2026.05.004_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190147","article-title":"Policies for biosimilar uptake in Europe: an overview","volume":"12","author":"Moorkens","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0098","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.dld.2026.05.004_bib0099","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2018.08.064","article-title":"Switching between biologics and biosimilars in inflammatory bowel disease","volume":"17","author":"Raffals","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.dld.2026.05.004_bib0100","doi-asserted-by":"crossref","first-page":"414","DOI":"10.37765\/ajmc.2025.89774","article-title":"US health care disparities in immunology biologics access: a systematic review","volume":"31","author":"Wright","year":"2025","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.dld.2026.05.004_bib0101","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3899\/jrheum.171148","article-title":"Too little Too late: effect of poor access to biologics for patients with rheumatoid arthritis","volume":"44","author":"Johnson","year":"2017","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0102","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1186\/s12913-022-08866-7","article-title":"Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades","volume":"22","author":"B\u00fcssgen","year":"2022","journal-title":"BMC Health v Res"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0103","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hec.4819","article-title":"Harmonizing regulatory market approval of products with high safety requirements: evidence from the European pharmaceutical market","volume":"33","author":"Gr\u00fcnwald","year":"2024","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0104","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1186\/s12913-022-08866-7","article-title":"Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades","volume":"22","author":"B\u00fcssgen","year":"2022","journal-title":"BMC Health v Res"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0105","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hec.4819","article-title":"Harmonizing regulatory market approval of products with high safety requirements: evidence from the European pharmaceutical market","volume":"33","author":"Gr\u00fcnwald","year":"2024","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.33393\/abtpn.2020.2184","article-title":"Time to reimbursement and negotiation condition in Italy for drugs approved by the European medicines agency during the period 2014-2019","volume":"7","author":"Prada","year":"2020","journal-title":"abtpn"},{"issue":"3","key":"10.1016\/j.dld.2026.05.004_bib0107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.therap.2021.12.007","article-title":"Epidemiology and economic burden of \u201cserious\u201d adverse drug reactions: real-world evidence research based on pharmacovigilance data","volume":"77","author":"Tissot","year":"2022","journal-title":"Therapie"},{"issue":"9","key":"10.1016\/j.dld.2026.05.004_bib0108","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40264-020-00946-z","article-title":"Patient-reported burden of adverse drug reactions attributed to biologics used for immune-mediated inflammatory diseases","volume":"43","author":"van Lint","year":"2020","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0109","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ajd.14153","article-title":"Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia","volume":"64","author":"Sullivan","year":"2023","journal-title":"Australas J Dermatol"},{"issue":"12","key":"10.1016\/j.dld.2026.05.004_bib0110","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.3390\/biomedicines10123280","article-title":"Effectiveness and safety profiles of biological therapies in inflammatory bowel disease: real life data from an active pharmacovigilance project","volume":"10","author":"Barbieri","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.dld.2026.05.004_bib0111","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.dld.2026.05.004_bib0112","first-page":"SP338","article-title":"Cost of biologic treatment persistence or switching in rheumatoid arthritis","volume":"24","author":"Gu","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.dld.2026.05.004_bib0113","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dld.2026.05.004_bib0114","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","article-title":"Patient reported outcomes in rheumatoid arthritis clinical trials","volume":"17","author":"Orbai","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.dld.2026.05.004_bib0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s41687-022-00524-0","article-title":"Patient and healthcare provider perceptions on using patient-reported experience measures (PREMs) in routine clinical care: a systematic review of qualitative studies","volume":"6","author":"Shunmuga Sundaram","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.dld.2026.05.004_bib0116","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.dld.2026.05.004_bib0117","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.clinthera.2014.06.014","article-title":"Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study","volume":"36","author":"Wu","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.dld.2026.05.004_bib0118","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.dld.2026.05.004_bib0119","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.clinthera.2014.06.014","article-title":"Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study","volume":"36","author":"Wu","year":"2014","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.dld.2026.05.004_bib0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14712598.2024.2378090","article-title":"Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease","volume":"24","author":"Lichtenstein","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.dld.2026.05.004_bib0121","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"}],"updated-by":[{"DOI":"10.1016\/j.dld.2026.07.078","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000}},{"DOI":"10.1016\/j.dld.2026.07.078","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:27:08Z","timestamp":1784719628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826007309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":119,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1590865826007309"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.05.004","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}